Back to Search

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

  • Protocol Number: 201904114
  • Principal Investigator: Mehta-Shah, Neha
  • Cancer Types: Lymphoma

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions